PAIB-SOs-12

PAIB-SOs-12 (compound 12) (48 h) potently inhibits the proliferation of MCF7 breast cancer cells expressing CYP1A1, with an IC₅₀ of 50 nM, and exhibits over 100-fold selectivity against CYP1A1-negative HT-29 and M21 cells^[1].
PAIB-SOs-12 (65 nM; 48 h) disrupts the microtubule cytoskeleton of MCF7 breast cancer cells expressing CYP1A1^[1].
PAIB-SOs-12 (48 h) potently inhibits the proliferation of HT-1080^{TM A[1]} cells expressing CYP1A1, with an IC₅₀ of 30 nM; it exhibits >167-fold and 152-fold selectivity, respectively, compared with CYP1A1-null HT-1080 empty vector cells and wild-type HT-1080 cells^[1].
PAIB-SOs-12 (400 nM; 0-60 min) exhibits superior stability in rodent liver, with a half-life of 111 min in mouse liver microsomes (MLMs), 160 min in rat liver microsomes (RLMs), and a sustained half-life of 120 min in human liver microsomes^[1].
PAIB-SOs-12 (32-31600 nM; 15 min) exhibits affinity for human CYP1A1, with a competitive inhibition constant (K_i) of 1.2 μM^[1].
PAIB-SOs-12 (145 nM; 48 h) induces G2/M cell cycle arrest in MCF7 breast cancer cells expressing CYP1A1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.